{"id":"NCT01772147","sponsor":"GlaxoSmithKline","briefTitle":"Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.","officialTitle":"A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2013-01-21","resultsPosted":"2014-04-21","lastUpdate":"2017-03-23"},"enrollment":608,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"Umeclidinium bromide 62.5mcg","otherNames":[]},{"type":"DRUG","name":"Umeclidinium bromide 125mcg","otherNames":[]},{"type":"DRUG","name":"Fluticasone propionate 250mcg/Salmeterol 50mcg","otherNames":[]}],"arms":[{"label":"Umeclidinium bromide","type":"EXPERIMENTAL"},{"label":"Fluticasone propionate/Salmeterol","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily and umeclidinium bromide (125mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily with placebo when added to fluticasone propionate (250/50mcg) twice-daily on lung function, COPD-related health status assessments and safety in COPD subjects.","primaryOutcome":{"measure":"Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85","timeFrame":"Baseline and Day 85","effectByArm":[{"arm":"Placebo QD + FSC 250/50 µg BID","deltaMin":-0.001,"sd":0.0136},{"arm":"UMEC 62.5 µg QD + FSC 250/50 µg BID","deltaMin":0.126,"sd":0.0133},{"arm":"UMEC 125 µg QD + FSC 250/50 µg BID","deltaMin":0.147,"sd":0.0132}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":15},"locations":{"siteCount":55,"countries":["United States","Chile","Czechia","Poland","South Korea"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":201},"commonTop":["Nasopharyngitis","Headache"]}}